Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420272 | 0.90 | NR1H2 (0.51) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL2417915 | 0.87 | MEN1 (0.52) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL2419414 | 0.87 | MEN1 (0.52) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL31050093 | 0.87 | MEN1 (0.52) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL2418785 | 0.87 | MEN1 (0.52) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL2419355 | 0.85 | P2RY12 (0.62) | MEN1KMT2AP2RY12 | |
| SCHEMBL2419418 | 0.84 | CXCR3 (0.51) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL2366192 | 0.83 | MEN1 (0.55) | NR1H2NR1H3MEN1KMT2AGPR119 | |
| SCHEMBL4109651 | 0.83 | P2RY12 (0.56) | NR1H2NR1H3MEN1KMT2AP2RY12 | |
| SCHEMBL18837997 | 0.83 | NR1H2 (0.82) | NR1H2NR1H3MEN1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204017-A | Benzisoxazole compounds | 国立大学法人大阪大学 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | NR1H2 342/4885NR1H3 290/4885MEN1 3672/4885 |
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | NR1H2 340/4885NR1H3 284/4885MEN1 3694/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | NR1H2 342/4885NR1H3 290/4885MEN1 3672/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | NR1H2 352/4885NR1H3 297/4885MEN1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.